Jay Parrish

Chairman and CEO

2021 - Current

Developing treatments to address the genetic roots of mitochondrial dysfunction

Venture Partner

2016

We’re catalyzing discoveries that prevent, detect, and cure disease

Chairman of the Board

2020

Series A company focused on small molecule solutions to several types of kidney stones (oxalate and cystine) and high-recurrent patient populations within. Formerly known as GyanRx.

Co-Founder and Board Member

2022

Strategic Advisor

2023

Magnet Biomedicine’s modular TrueGlue™ technology enables the systematic discovery of molecular glues towards the treatment of human disease. https://magnetbio.com

Co-Founder and Member Board Of Directors

2019

Harnessing the power of the repeatome to develop a new class of therapies for cancer and autoimmune diseases

Strategic Advisor

2022

Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible

Board Observer

2021

Gate Bioscience is developing Molecular Gates, a new frontier in protein elimination

Member Board Of Directors

2021

Interline Therapeutics is a drug discovery company focused on systematically elucidating protein communities to define molecular mechanisms of disease.

Strategic Advisor

2021 - 2024

Sold to Biogen for $1.8B ($1.15B upfront and $650M in milestones)